Conference Recap: CHEST 2024

This year’s annual meeting of the American College of Chest Physicians, CHEST 2024, took place October 6 to 9 in Boston, Massachusetts and featured some of the latest in cutting-edge clinical education. Over the course of 4 days at the Boston Convention and Exhibition Center, attendees got the chance to see more than 300 educational sessions, gain insights from over 600 faculty members, and earn 29.5 hours of CE credits.

Conference Recap: CHEST 2024 / SeanPavonePhoto - stock.adobe.com

Drug Topics provided virtual coverage of some of the most important conversations taking place at the event. Check out the list below to catch up on some of the latest clinical research on COVID-19, COPD, Asthma and more that was presented at CHEST 2024.

Examining Flu, COVID-19 Infection Outcomes in Children

Three research posters presented at the meeting examined outcomes of COVID-19 on patients with alcoholic liver disease, cirrhosis, and non-alcohol steatohepatitis (NASH).

COVID-19 Infection Raises Heart Failure Risks, Underlines Vaccination Importance

COVID-19 infection may lead to worse heart failure (HF) outcomes, including longer hospital stays, increased need for ventilation, and higher mortality rates, according to an abstract presented at the meeting.

Prednisone Superior to Other Corticosteroids for Patients with COPD, Heart Failure

Patients with a dual diagnosis of chronic obstructive pulmonary disease (COPD) and heart failure who take prednisone have shorter hospital stays compared to patients given other corticosteroids, according to research data presented at the meeting.

Assessing the Efficacy of Mepolizumab in Asthma, COPD

Two research posters presented at the meeting reported on how mepolizumab can improve asthma control, and reduce exacerbations of concurrent asthma and chronic obstructive pulmonary disease (COPD).

Examining the Impact of COVID-19 on Patients with Liver Disease

Three posters presented at the meeting examined outcomes of COVID-19 on patients with alcoholic liver disease, cirrhosis, and non-alcohol steatohepatitis (NASH).

Exploring Challenges in Diagnosis, Treatment of Asthma-COPD Overlap Syndrome

Two posters presented at the meeting explored the challenges of asthma-COPD overlap syndrome (ACOS) diagnosis and offered insights into appropriate treatment.

Be sure to check out all our CHEST 2024 coverage here.

Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our free Drug Topics newsletter.